Highly rated in
Highly rated in
Check Dr. Erik A. Imel's experience treating your condition:
About Dr. Erik A. Imel

Erik Imel is an Endocrinologist and a Pediatrics expert in Indianapolis, Indiana. Imel has been practicing medicine for over 23 years and is highly rated in 17 conditions, according to our data. His top areas of expertise are Hypophosphatemia, X-Linked Hypophosphatemia, Rickets, and Malnutrition. He is licensed to treat patients in Indiana. Imel is currently accepting new patients.

His clinical research consists of co-authoring 68 peer reviewed articles and participating in 7 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Erik A. Imel it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Erik A. Imel accepts the following insurance:

  •  Ambetter
  •  Anthem
  •  CareSource
  •  MHS

Call to see if your plan is accepted.
550 N University Blvd, Indianapolis, IN 46202
Other Locations
705 Riley Hospital Dr, Room 5867, Indianapolis, IN 46202
Background & Education
Graduate Institution
University Of Cincinnati College Of Medicine, 1999
Pediatrics in IN
Hospital Affiliations
IU Health Methodist Hospital
Good Samaritan Hospital
Eskenazi Health
Parkview Wabash Hospital
IU Health North Hospital
Union Hospital
Riley Hospital For Children At IU Health
IU Health Ball Memorial Hospital
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders: a Pilot Study
Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot
An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis
View 6 Less Clinical Trials -

68 Total Publications

Approach to Hypophosphatemic Rickets.

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors